

Cancer Endorsement Maintenance 2011-Maintenance Measures

Measure Number	Title	Description	Measure Steward
0210	Proportion receiving chemotherapy in the last 14 days of life	Percentage of patients who died from cancer receiving chemotherapy in the last 14 days of life	American Society of Clinical Oncology
0211	Proportion with more than one emergency room visit in the last days of life	Percentage of patients who died from cancer with more than one emergency room visit in the last days of life	American Society of Clinical Oncology
0212	Proportion with more than one hospitalization in the last 30 days of life	Percentage of patients who died from cancer with more than one hospitalization in the last 30 days of life	American Society of Clinical Oncology
0213	Proportion admitted to the ICU in the last 30 days of life	Percentage of patients who died from cancer admitted to the ICU in the last 30 days of life	American Society of Clinical Oncology
0214	Proportion dying from Cancer in an acute care setting	Percentage of patients who died from cancer dying in an acute care setting	American Society of Clinical Oncology
0215	Proportion not admitted to hospice	Percentage of patients who died from cancer not admitted to hospice	American Society of Clinical Oncology
0216	Proportion admitted to hospice for less than 3 days	Percentage of patients who died from cancer, and admitted to hospice and spent less than 3 days there	American Society of Clinical Oncology
0219	Post breast conserving surgery irradiation	Percentage of female patients, age 18-69, who have their first diagnosis of breast cancer (epithelial malignancy), at AJCC stage I, II, or III, receiveing breast conserving surgery who receive radiation therapy within 1 year (365 days) of diagnosis	American College of Surgeons
0220	Adjuvant hormonal therapy	Percentage of female patients, age >18 at diagnosis, who have their first diagnosis of breast cancer (epithelial malignancy), at AJCC stage I, II, or III, who's primary tumor is progesterone or estrogen receptor positive recommended for tamoxifen or third generation aromatase inhibitor (considered or administered) within 1 year (365 days) of diagnosis	American College of Surgeons

Cancer Endorsement Maintenance 2011-Maintenance Measures

0221	Needle biopsy to establish diagnosis of cancer precedes surgical excision/resection	Percentage of patients presenting with AJCC Stage Group 0, I, II, or III disease, who undergo surgical excision/resection of a primary breast tumor who undergo a needle biopsy to establish diagnosis of cancer preceding surgical excision/resection	American College of Surgeons
0222	Patients with early stage breast cancer who have evaluation of the axilla	Percentage of women with Stage I-IIb breast cancer that received either axillary node dissection or Sentinel Lymph Node Biopsy (SLNB) at the time of surgery (lumpectomy or mastectomy)	Intermountain Healthcare
0223	Adjuvant chemotherapy is considered or administered within 4 months (120 days) of surgery to patients under the age of 80 with AJCC III (lymph node positive) colon cancer	Percentage of patients under the age of 80 with AJCC III (lymph node positive) colon cancer for whom adjuvant chemotherapy is considered or administered within 4 months (120 days) of surgery	American College of Surgeons
0224	Completeness of pathology reporting	Percentage of patients with audited colorectal cancer resection pathology complete reports	American College of Surgeons, National Cancer Institute
0225	At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer	Percentage of patients >18yrs of age, who have primary colon tumors (epithelial malignancies only), experiencing their first diagnosis, at AJCC stage I, II or III who have at least 12 regional lymph nodes removed and pathologically examined for resected colon cancer	American College of Surgeons
0377	Myelodysplastic Syndrome (MDS) and Acute Leukemias – Baseline Cytogenetic Testing Performed on Bone Marrow	Percentage of patients aged 18 years and older with a diagnosis of MDS or an acute leukemia who had baseline cytogenetic testing performed on bone marrow.	American Medical Association - Physician Consortium for Performance Improvement
0378	Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	Percentage of patients aged 18 years and older with a diagnosis of MDS who are receiving erythropoietin therapy with documentation of iron stores prior to initiating erythropoietin therapy	American Medical Association - Physician Consortium for Performance Improvement

Cancer Endorsement Maintenance 2011-Maintenance Measures

0379	Chronic Lymphocytic Leukemia (CLL) – Baseline Flow Cytometry	Percentage of patients aged 18 years and older with a diagnosis of CLL who had baseline flow cytometry studies performed	American Medical Association - Physician Consortium for Performance Improvement
0380	Multiple Myeloma – Treatment with Bisphosphonates	Percentage of patients aged 18 years and older with a diagnosis of multiple myeloma, not in remission, who were prescribed or received intravenous bisphosphonates within the 12 month reporting period	American Medical Association - Physician Consortium for Performance Improvement
0381	Oncology: Treatment Summary Documented and Communicated – Radiation Oncology	Percentage of patients with a diagnosis of cancer who have undergone brachytherapy or external beam radiation therapy who have a treatment summary report in the chart that was communicated to the physician(s) providing continuing care within one month of completing treatment	American Medical Association - Physician Consortium for Performance Improvement
0382	Oncology: Radiation Dose Limits to Normal Tissues	Percentage of patients with a diagnosis of cancer receiving 3D conformal radiation therapy with documentation in medical record that normal tissue dose constraints were established within five treatment days for a minimum of one tissue	American Medical Association - Physician Consortium for Performance Improvement
0383	Oncology: Plan of Care for Pain – Medical Oncology and Radiation Oncology (paired with 0384)	Percentage of visits for patients with a diagnosis of cancer currently receiving intravenous chemotherapy or radiation therapy who report having pain with a documented plan of care to address pain	American Medical Association - Physician Consortium for Performance Improvement
0384	Oncology: Pain Intensity Quantified – Medical Oncology and Radiation Oncology (paired with 0383)	Percentage of visits for patients with a diagnosis of cancer currently receiving intravenous chemotherapy or radiation therapy in which pain intensity is quantified	American Medical Association, American Medical Association - Physician Consortium for Performance Improvement
0385	Oncology: Chemotherapy for Stage IIIA through IIIC Colon Cancer Patients	Percentage of patients aged 18 years and older with Stage IIIA through IIIC colon cancer who are prescribed or who have received adjuvant chemotherapy within the 12 month reporting period	American Medical Association - Physician Consortium for Performance Improvement

Cancer Endorsement Maintenance 2011-Maintenance Measures

0386	Oncology: Cancer Stage Documented Cancer stage documented	Percentage of patients with a diagnosis of breast, colon, or rectal cancer seen in the ambulatory setting who have a baseline AJCC cancer stage or documentation that the cancer is metastatic in the medical record at least once during the 12 month reporting period	American Medical Association - Physician Consortium for Performance Improvement
0387	Oncology: Hormonal therapy for stage IC through IIIC, ER/PR positive breast cancer	Percentage of female patients aged 18 years and older with Stage IC through IIIC, estrogen receptor (ER) or progesterone receptor (PR) positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) within the 12 month reporting period	American Medical Association - Physician Consortium for Performance Improvement
0388	Prostate Cancer: Three-Dimensional Radiotherapy	Percentage of patients with prostate cancer receiving external beam radiotherapy to the prostate only who receive 3D-CRT (three-dimensional conformal radiotherapy) or IMRT (intensity modulated radiation therapy)	American Medical Association - Physician Consortium for Performance Improvement
0389	Prostate Cancer: Avoidance of Overuse Measure – Isotope Bone Scan for Staging Low-Risk Patients	Percentage of patients with a diagnosis of prostate cancer, at low risk of recurrence, receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer	American Medical Association - Physician Consortium for Performance Improvement
0390	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Patients	Percentage of patients with a diagnosis of prostate cancer, at high risk of recurrence, receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH agonist or antagonist)	American Medical Association - Physician Consortium for Performance Improvement
0391	Breast Cancer Resection Pathology Reporting- pT category (primary tumor) and pN category (regional lymph nodes) with histologic grade	Percentage of breast cancer resection pathology reports that include the pT category (primary tumor), the pN category (regional lymph nodes) and the histologic grade	American Medical Association - Physician Consortium for Performance Improvement

Cancer Endorsement Maintenance 2011-Maintenance Measures

0392	Colorectal Cancer Resection Pathology Reporting- pT category (primary tumor) and pN category (regional lymph nodes) with histologic grade	Percentage of colon and rectum cancer resection pathology reports that include the pT category (primary tumor), the pN category (regional lymph nodes) and the histologic grade	American Medical Association - Physician Consortium for Performance Improvement
0559	Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1c, or Stage II or III hormone receptor negative breast cancer.	Percentage of female patients, age >18 at diagnosis, who have their first diagnosis of breast cancer (epithelial malignancy), at AJCC stage I, II, or III, who's primary tumor is progesterone and estrogen receptor negative recommended for multiagent chemotherapy (considered or administered) within 4 months (120 days) of diagnosis.	American College of Surgeons
0561	Melanoma Coordination of Care	Percentage of patients seen with a new occurrence of melanoma who have a treatment plan documented in the chart that was communicated to the physician(s) providing continuing care within one month of diagnosis	American Medical Association, American Medical Association - Physician Consortium for Performance Improvement
0562	Over Utilization of Imaging Studies in Stage 0-IA Melanoma	Percentage of patients with stage 0 or IA melanoma, without signs or symptoms, for whom no diagnostic imaging studies were ordered	American Medical Association, American Medical Association - Physician Consortium for Performance Improvement
0572	Follow-up after initial diagnosis and treatment of colorectal cancer: colonoscopy	To ensure that all eligible members who have been newly diagnosed and resected with colorectal cancer receive a follow-up colonoscopy within 15 months of resection.	Health Benchmarks, Inc, IMS Health
0623	Breast Cancer -Cancer Surveillance	Percentage of female patients with breast cancer who had breast cancer surveillance in the past 12 months	ActiveHealth Management
0625	Prostate Cancer - Cancer Surveillance	Percentage of males with prostate cancer that have had their PSA monitored in the past 12 months	ActiveHealth Management

Cancer Endorsement Maintenance 2011-Maintenance Measures

0650	Melanoma Continuity of Care – Recall System	Percentage of patients with a current diagnosis of melanoma or a history of melanoma who were entered into a recall system with the date for the next complete physical skin exam specified, at least once within the 12 month reporting period	
-------------	---	---	--